Primary and Secondary Long-Term Prophylaxis of Thromboembolism in Outpatients with the Low-Molecular-Weight Heparin Kabi 2165

1988 ◽  
Vol 18 (3) ◽  
pp. 78-81
Author(s):  
J. Harenberg ◽  
G. Leber ◽  
R. Raedsch ◽  
R. Zimmermann ◽  
F. Schwarz ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight

Antithrombotic Therapy for DVT/PE

1997 ◽  
Vol 17 (03) ◽  
pp. 161-162
Author(s):  
Thomas Hyers
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Oral Anticoagulants ◽  
Cost Effective ◽  
Therapeutic Agents ◽  
Great Promise ◽  
Term Therapy ◽  
Low Molecular Weight ◽  
Long Term Therapy

SummaryProblems with unfractionated heparin as an antithrombotic have led to the development of new therapeutic agents. Of these, low molecular weight heparin shows great promise and has led to out-patient therapy of DVT/PE in selected patients. Oral anticoagulants remain the choice for long-term therapy. More cost-effective ways to give oral anticoagulants are needed.

Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy: The Balance of Benefits and Harms

2007 ◽  
Vol 120 (1) ◽  
pp. 72-82.e3 ◽  
Author(s):  
Russell D. Hull ◽  
Graham F. Pineo ◽  
Rollin F. Brant ◽  
Andrew F. Mah ◽  
Natasha Burke ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Heparin Therapy ◽  
Low Molecular Weight

Intermediate doses of low-molecular-weight heparin for the long-term treatment of pregnancy thromboembolism. A systematic review

2014 ◽  
Vol 111 (03) ◽  
pp. 559-561 ◽  
Author(s):  
Esteban Gándara ◽  
Marc Carrier ◽  
Marc Rodger
Keyword(s):  
Systematic Review ◽  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Term Treatment ◽  
Low Molecular Weight ◽  
Contact Information ◽  
Long Term Treatment ◽  
E Mail

Note: The contact information for Drs. Gandara and Carrier is the same as for Dr. Rodger. Their e-mail addresses are [email protected] and [email protected], respectively.

Homozygous Protein C Deficiency: Description of a New Mutation and Successful Treatment with Low Molecular Weight Heparin

1998 ◽  
Vol 79 (04) ◽  
pp. 756-761 ◽  
Author(s):  
Paul Monagle ◽  
Maureen Andrew ◽  
Jacqueline Halton ◽  
Richard Marlar ◽  
Lawrence Jardine ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Bone Density ◽  
Skin Necrosis ◽  
Protein C ◽  
Low Molecular Weight Heparin ◽  
Whole Body ◽  
Term Therapy ◽  
Low Molecular Weight ◽  
New Mutation

SummaryWe present a kindred with a new mutation of the protein C gene, in which the proband had an unusual clinical presentation. The relationship between warfarin induced skin necrosis and level of anticoagulation was investigated. The pharmacokinetics of protein C concentrate was assessed to determine frequency of replacement therapy. The clinical and biochemical efficacy of therapy with low molecular weight heparin (LMWH) was assessed. The effect of long-term LMWH on bone density in the growing child was monitored using whole body densitometry.Warfarin therapy required an INR of greater than 3.5 to avoid skin necrosis. If protein C replacement was to be used, doses of 100 U/kg/day would have been required to maintain protein C levels consistently at or above 0.20 U/ml. While receiving prophylactic therapy with LMWH for almost 3 years, there were no episodes of recurrent thrombosis, no skin necrosis and no bleeding. Biochemical markers of in vivo thrombin generation were suppressed and within the normal range. Bone density continued to increase at the normal rate throughout the treatment period.LMWH is an effective form of long-term therapy for homozygous protein C deficient patients with measurable protein C levels.

Sign in / Sign up

Export Citation Format

Share Document